Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Verisign, Inc. (VRSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Verisign, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Verisign, Inc. trades at $270.69 (market cap $24.58B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.2% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VRSN | |
|---|---|---|
Market Cap | $39.89B | $24.58B |
Sector | Health | Technology |
52-Week High | $491.22 | $310.00 |
52-Week Low | $278.09 | $211.49 |
Enterprise Value | $38.15B | $25.82B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
VeriSign (VRSN) trades at $270.11, up 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.67. The company reported Q1 2026 EPS of $2.34, beating expectations, and maintains strong profitability with a net income margin near 50%. Recent news highlights AI-driven domain registration growth and the upcoming Q2 2026 earnings report on July 23, 2026.
The outlook for VRSN is positive, supported by stable revenue growth, high margins, and analyst optimism, but risks include AI disruption to its domain business, contract renewals, and a high debt load. The stock offers potential upside to the consensus target, though investors should monitor earnings execution and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
